Comparing Diuretic Strategies in Hospitalized Heart Failure

Heart Failure Clinical Trial

Official title:

Creating a Platform for Point-of-Care Pragmatic Clinical Trials: Comparing Diuretic Strategies in Heart Failure

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03999216
• Other study ID #: 51720
• Status: Withdrawn
• Phase: Phase 4
• Start date: July 2023
• Est. completion date: June 2024

Study information

• Verified date: April 2023
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

We will conduct a pragmatic randomized trial comparing whether using a combination of two types of diuretics (loop + thiazide) compared with using a single diuretic (loop only) will result in shorter hospital stays for patients hospitalized with heart failure.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 2024
• Est. primary completion date: January 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Any adult (age =18 years) admitted to the Heart Failure Service at Stanford Health Care with an indication for treatment with a diuretic.

Exclusion Criteria:

1. admission to the intensive care unit or cardiac care units

2. maintenance dialysis on admission

3. any mechanical circulatory support on admission

4. history of heart transplant

5. allergy / intolerance to loop or thiazide diuretics

6. admission serum sodium < 125 meq/L (from EPIC)

7. admission serum potassium < 3.0 meq/L (from EPIC)

Related Conditions & MeSH terms

• Heart Failure

Intervention

Drug:
• Loop Diuretics vs. loop + thiazide diuretics
Participants will receive the diuretic type as determined by the randomized group assignment starting within the first 24 hours of hospital admission and continuing for up to 72 hours. All other treatments are left to the discretion of the treatment team, as this is a pragmatic randomized trial.

Locations

Country	Name	City	State
United States	Stanford Health Care	Palo Alto	California

Sponsors (2)

Lead Sponsor	Collaborator
Stanford University	American Heart Association

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hospital length of stay		During hospitalization up to 90 days
Secondary	Composite of all-cause rehospitalizations, emergency department visits, or death in the 30 days after hospital discharge.		30 days